/
Oncology
Carcinoma
23
Pipeline Programs↗
7
Active Trials↗
15
Companies Involved↗
Carcinoma is an emerging landscape with 23 programs across 15 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Phio Pharmaceuticals Inc.. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Phase 24
Approved
No programs
Analysis
Modality Breakdown
95%
Small molecule
21 of 22 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.
Analysis
Trial Status
47
clinical trials
Completed22 · 47%
Unknown status8 · 17%
Terminated6 · 13%
Recruiting4 · 9%
Withdrawn3 · 6%
Active, not recruiting2 · 4%
Other2 · 4%
Clinical Trials
Trial Activity
47 trials
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
Recruiting·—·Phase 2/3·NCT05833815·56 enrolled
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.
Active, not recruiting·
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05987358·165 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05987358·165 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)